About Cyted
Cyted is a company based in Cambridge (United Kingdom) founded in 2018 by Maria O'Donovan, Maria Odonovan, Marcel Gehrung, and Rebecca Fitzgerald. Cyted has raised $50.44 million across 6 funding rounds from investors including British Business Bank, EQT and Advent Life Sciences. Cyted offers products and services including EndoSign, Pathology Services, and Clinical Research. Cyted operates in a competitive market with competitors including Apollo Endo, Valar Labs, NEOGAP, Azra and Oncora, among others.
- Headquarter Cambridge, United Kingdom
- Founders Maria O'Donovan, Maria Odonovan, Marcel Gehrung, Rebecca Fitzgerald
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cyted Ltd
- Date of Incorporation 23 Jul, 2018
- Jurisdiction CAMBRIDGE, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$50.44 M (USD)
in 6 rounds
-
Latest Funding Round
$43.82 M (USD), Series B
Sep 01, 2025
-
Investors
British Business Bank
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cyted
Cyted offers a comprehensive portfolio of products and services, including EndoSign, Pathology Services, and Clinical Research.
Fast test for detecting esophageal pre-cancer and diseases.
Services for analyzing gastrointestinal health samples.
Platform for studying and validating digestive disease diagnostics.
Funding Insights of Cyted
Cyted has successfully raised a total of $50.44M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $43.82 million completed in September 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cyted
Cyted has secured backing from 5 investors, including venture fund investors. Prominent investors backing the company include British Business Bank, EQT and Advent Life Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
EQT is recognized as a global investment organization focused on value creation.
|
Locked | Locked | Locked | |
|
Early and mid-stage life science focused VC firm investing in the US and Europe
|
Locked | Locked | Locked | |
|
Private debt fund and fund of funds focused on startups
|
Locked | Locked | Locked |
Investor details for Cyted
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cyted
Investment portfolio details for Cyted
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cyted
Detailed financials for Cyted
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cyted Comparisons
Peer comparison for Cyted
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cyted
Cyted operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Apollo Endo, Valar Labs, NEOGAP, Azra and Oncora, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutic devices for obesity and GI disorders are developed.
|
|
| Locked | Locked | Locked |
AI software for oncology treatment planning is provided to providers.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for cancer treatment are developed using advanced technologies.
|
|
| Locked | Locked | Locked |
Oncology workflows are automated through AI and machine learning.
|
|
| Locked | Locked | Locked |
AI-based clinical data analysis and decision support tool for oncologists
|
|
| Locked | Locked | Locked |
Developer of medical devices and biomarkers to detect various diseases
|
Detailed competitors of Cyted
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cyted
Complete news archive for Cyted
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cyted
Cyted was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Cyted is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Marcel Gehrung is the current CEO of Cyted. They have also founded this company.
Cyted is a funded company, having raised a total of $50.44M across 6 funding rounds to date.
Cyted was founded in 2018 in Cambridge, United Kingdom, as a gastrointestinal health company. Non-endoscopic diagnostic technologies are pioneered to identify digestive diseases at early stages. Access to care is expanded through these innovations, with operations centered on improving patient outcomes in the diagnostics sector. Leadership includes co-founders such as Marcel Gehrung as CEO and Rebecca Fitzgerald as CSO.
Cyted's top competitors include Apollo Endo, Valar Labs and PAVmed.
Cyted offers EndoSign, Pathology Services, and Clinical Research.
Cyted has 5 investors. Key investors include British Business Bank, EQT, Advent Life Sciences, Morningside, and BGF.